An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients
Nicole G. Chau(University of British Columbia), Christopher A. French(Harvard University), Kristina Danga(Brigham and Women's Hospital), Geoffrey I. Shapiro(Brigham and Women's Hospital), Valentina Nardi(Biopredic (France)), Christopher S. Lathan(Harvard University), Steven G. DuBois(University of California, San Francisco), Stephen E. Sallan, Clement Ma(University of Toronto), Arindam Dhar(GlaxoSmithKline (United States)), Hasan Al‐Sayegh(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Jeanenne J. Nelson(GlaxoSmithKline (United States)), Robert I. Haddad(Georgetown University), Ryan Barrette(Brigham and Women's Hospital)
Cited by 226
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914